文献速递淋巴瘤造血干细胞移植与细胞治疗

血液肿瘤患者接受CAR-T治疗后出现持续性血液学毒性

Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies.
PubMed 文献 · Am J Hematol · 2021-02-24

单中心回顾性分析31例接受商业CAR-T治疗的复发/难治弥漫大B细胞淋巴瘤成人患者,58%发生持续性血液学毒性(PHT,定义为CAR-T后第30天≥3级中性粒细胞减少或血小板减少)。PHT患者1年总生存率低于无PHT者(36% vs 81%,P<.05),并鉴定出CRS、托珠单抗/类固醇使用、高铁蛋白及高CRP等关联因素。

要点

  • CAR-T后第30天≥3级中性粒细胞减少或血小板减少定义为持续性血液学毒性(PHT)。
  • PHT发生率58%,与1年总生存率降低相关(36% vs 81%,P<.05)。
  • CRS、托珠单抗/类固醇使用、铁蛋白>5000 ng/ml、CRP>100 mg/L与PHT相关。

核心结论

  • PHT是CAR-T治疗相关的重要毒性,与更差的1年OS相关,需更大样本研究和管理标准。

研究设计与样本

  • 单中心回顾性研究,纳入2018年3月1日至2020年5月30日接受商业CAR-T治疗的31例成人复发/难治弥漫大B细胞淋巴瘤患者。

主要发现

  • 31例中18例(58%)发生PHT。
  • PHT患者1年OS为36%,无PHT患者为81%(P<.05)。
  • PHT与无PHT患者中性粒细胞绝对计数恢复中位时间无差异(16天 vs 15天)。
  • 7例PHT患者CAR-T后骨髓活检均示完全再生障碍或细胞增生低下(细胞面积5%至10%)。

关键数值与推荐

  • PHT定义为CAR-T后第30天≥3级中性粒细胞减少或血小板减少。
  • CRS与PHT相关(P=.002);托珠单抗使用(P=.002)和类固醇使用(P=.033)与PHT相关。
  • 铁蛋白峰值>5000 ng/ml(P=.048)和CRP峰值>100 mg/L(P=.007)与PHT相关。
  • 第30天铁蛋白高于正常上限与PHT相关。

临床怎么用

  • 对CAR-T后第30天仍存在≥3级血细胞减少的患者应警惕PHT并加强监测。
  • 发生CRS或使用托珠单抗/类固醇、铁蛋白或CRP显著升高的患者可能需关注PHT风险。

局限性

  • 单中心回顾性研究,样本量较小(31例)。
  • PHT定义仅基于第30天血细胞计数,未涉及更长期随访。
  • 需更大队列研究验证PHT风险因素和管理标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor T-cell therapy (CAR T) is a novel intervention for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and other hematologic malignancies. However, it is associated with prolonged hematologic toxicity (PHT) that is unpredictable and can significantly impair patients' quality of life. Reported here is a single-center experience with PHT in adult patients with R/R DLBCL who received commercial CAR T-cell therapy between March 1, 2018 and May 30, 2020. Prolonged hematologic toxicity was defined as ≥ grade 3 neutropenia or thrombocytopenia at day +30 after CAR T-cell therapy. Of the 31 patients identified, 18 patients (58%) developed PHT. Patients with PHT had a shorter 1-year overall survival (OS) than patients without PHT (36% vs. 81%, P < .05). There were no differences in the median time to ANC recovery for those with PHT compared to patients without PHT (16 days vs. 15 days). Several risk factors were identified to be associated with PHT including CRS (P = .002), receipt of tocilizumab (P = .002) or steroids (P = .033), peak ferritin >5000 ng/ml (P = .048), peak C-reactive protein (CRP) > 100 mg/L (P = .007), and ferritin greater than the upper limit of normal at day +30. Seven patients with PHT underwent a bone marrow biopsy after CAR T-cell therapy; all showed complete aplasia or were hypocellular with cellularity ranging from <5% to 10%. These findings identify PHT as a significant toxicity associated with CAR T-cell therapy and highlight the critical need for further investigations to describe PHT in larger cohorts and identify standards for management of this condition.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Nagle SJ, Murphree C, Raess PW, et al. Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies. Am J Hematol. 2021. PMID: 33529419. doi:10.1002/ajh.26113

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。